Becton Dickinson & Co (BDX): Jeffrey S Sherman , Sr. VP and General Counsel of Becton Dickinson & Co sold 34,373 shares on May 17, 2016. The Insider selling transaction was reported by the company on May 18, 2016 to the Securities and Exchange Commission. The shares were sold at $166.27 per share for a total value of $5,715,199.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 16, 2016, Vincent A Forlenza (Chairman, CEO and President) sold 37,933 shares at $166.17 per share price.On May 16, 2016, Stephen Sichak (Executive Vice President) sold 12,995 shares at $166.48 per share price.Also, On May 11, 2016, James F Orr (director) sold 1,368 shares at $167.66 per share price.On May 10, 2016, Alexandre Conroy (Executive Vice President) sold 11,238 shares at $165.58 per share price.
Shares of Becton Dickinson and Co (BDX) ended Thursday, May 19, 2016 session in red amid volatile trading. The shares closed down -1.51 points or -0.91% at $163.94 with 11,27,633 shares getting traded. Post opening the session at $164.58, the shares hit an intraday low of $162.25 and an intraday high of $165.37 and the price vacillated in this range throughout the day. The company has a market cap of $34,788 M and the number of outstanding shares has been calculated to be 21,22,02,000 shares. The 52-week high of Becton Dickinson and Co is $169.08 and the 52-week low is $128.87.
Company has been under the radar of several Street Analysts.Becton Dickinson and Co is Reiterated by RBC Capital Mkts to Sector Perform and the brokerage firm has raised the Price Target to $ 169 from a previous price target of $153 .The Rating was issued on May 9, 2016.
Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.